Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.

ABSTRACT:

Background

A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with local regional therapy has elicited yield substantial clinical benefits in patients who have hepatocellular carcinoma (HCC) with extrahepatic metastases. Using this treatment strategy to convert HCC patients with extrahepatic metastases from unresectable to resectable has not yet been reported.

Methods

Consecutive hepatocellular carcinoma patients with extrahepatic metastases who received first-line therapy with a combination of TKIs and anti-PD-1 antibodies and at least one local regional therapy were analysed.

Results

Nine patients with localized disease who received first-line systemic therapy were enrolled. At baseline, all of them had oligometastatic disease, namely, Barce

SUBMITTER: Yang X 

PROVIDER: S-EPMC8350994 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature